Literature DB >> 25470107

Schizophrenia: overview and dopamine dysfunction.

Anissa Abi-Dargham1.   

Abstract

Schizophrenia is a chronic, often disabling illness that affects approximately 24 million people worldwide. Unfortunately, while the majority of first-episode schizophrenia patients respond well to initial antipsychotic treatment, less than 1 in 5 will maintain recovery over 2 to 5 years, and most will experience at least 1 relapse. Dopamine dysfunction helps to explain the positive symptoms experienced by patients with schizophrenia, and targeting these pathways has made current antipsychotics effective treatments for this condition. However, these agents primarily manage the positive symptoms of the disorder, while negative and cognitive symptoms can persist. More treatments are needed that comprehensively address all presentations of the disorder. © Copyright 2014 Physicians Postgraduate Press, Inc.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25470107     DOI: 10.4088/JCP.13078tx2c

Source DB:  PubMed          Journal:  J Clin Psychiatry        ISSN: 0160-6689            Impact factor:   4.384


  33 in total

1.  A comparison of psychotic symptoms in subjects with methamphetamine versus cocaine dependence.

Authors:  Peter D Alexander; Kristina M Gicas; Taylor S Willi; Clara N Kim; Veronika Boyeva; Ric M Procyshyn; Geoff N Smith; Allen E Thornton; William J Panenka; Andrea A Jones; Fidel Vila-Rodriguez; Donna J Lang; G William MacEwan; William G Honer; Alasdair M Barr
Journal:  Psychopharmacology (Berl)       Date:  2017-02-11       Impact factor: 4.530

2.  Virtual reality assessment of functional capacity in people with Schizophrenia: Associations with reduced emotional experience and prediction of functional outcomes.

Authors:  Philip D Harvey; Anzalee Khan; Alexandra Atkins; Richard Se Keefe
Journal:  Psychiatry Res       Date:  2019-01-15       Impact factor: 3.222

3.  Negative affect predicts social functioning across schizophrenia and bipolar disorder: Findings from an integrated data analysis.

Authors:  Tyler B Grove; Ivy F Tso; Jinsoo Chun; Savanna A Mueller; Stephan F Taylor; Vicki L Ellingrod; Melvin G McInnis; Patricia J Deldin
Journal:  Psychiatry Res       Date:  2016-06-25       Impact factor: 3.222

4.  A Phase-1, 6-Month Open-Label, Dose-Ranging Pharmacokinetic Study in Stabilized Patients with Schizophrenia Following Risperidone Implant.

Authors:  Ryan Dammerman; Sonnie Kim; Mathews Adera; Alex Schwarz
Journal:  Psychopharmacol Bull       Date:  2017-09-15

5.  NURR1 and ERR1 Modulate the Expression of Genes of a DRD2 Coexpression Network Enriched for Schizophrenia Risk.

Authors:  Silvia Torretta; Antonio Rampino; Manuela Basso; Giulio Pergola; Pasquale Di Carlo; Joo H Shin; Joel E Kleinman; Thomas M Hyde; Daniel R Weinberger; Rita Masellis; Giuseppe Blasi; Maria Pennuto; Alessandro Bertolino
Journal:  J Neurosci       Date:  2019-12-06       Impact factor: 6.167

6.  Organization of afferents to the orbitofrontal cortex in the rat.

Authors:  Monika J M Murphy; Ariel Y Deutch
Journal:  J Comp Neurol       Date:  2018-03-23       Impact factor: 3.215

7.  Altered Coupling Between Resting-State Cerebral Blood Flow and Functional Connectivity in Schizophrenia.

Authors:  Jiajia Zhu; Chuanjun Zhuo; Lixue Xu; Feng Liu; Wen Qin; Chunshui Yu
Journal:  Schizophr Bull       Date:  2017-10-21       Impact factor: 9.306

Review 8.  Using molecular imaging to understand early schizophrenia-related psychosis neurochemistry: a review of human studies.

Authors:  Christin Schifani; Sina Hafizi; Tania Da Silva; Jeremy Joseph Watts; M Saad Khan; Romina Mizrahi
Journal:  Int Rev Psychiatry       Date:  2017-12-08

9.  Class side effects: decreased pressure in the lower oesophageal and the pyloric sphincters after the administration of dopamine antagonists, neuroleptics, anti-emetics, L-NAME, pentadecapeptide BPC 157 and L-arginine.

Authors:  Zeljka Belosic Halle; Josipa Vlainic; Domagoj Drmic; Dean Strinic; Kresimir Luetic; Mario Sucic; Maria Medvidovic-Grubisic; Tatjana Pavelic Turudic; Igor Petrovic; Sven Seiwerth; Predrag Sikiric
Journal:  Inflammopharmacology       Date:  2017-05-17       Impact factor: 4.473

10.  Blood Pressure and Heart Rate Changes During Clozapine Treatment.

Authors:  Sarah M Norman; Kelli M Sullivan; Fang Liu; Bethany A DiPaula; Pedro A Jose; Christopher A Kitchen; Stephanie M Feldman; Deanna L Kelly
Journal:  Psychiatr Q       Date:  2017-09
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.